{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.5","upperLimit":"49.5","value":"35.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"Overall response rate was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) among all eligible and treated patients. Best overall response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. The 90% two-sided binomial exact confidence interval was calculated for ORR.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive nivolumab IV over 30-60 minutes on days 1 and 15 of cycles 1-4 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nNivolumab: Given IV","id":"OG000","title":"Treatment (Nivolumab)"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"assessed at baseline, then every 8 weeks for the first 2 years, then every 12 weeks in year 3, until disease progression","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}